Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25502863 | 0.86 | — | — | |
| SCHEMBL14012558 | 0.83 | CYP2D6 (0.39) | CYP2D6 | |
| SCHEMBL21965035 | 0.79 | CYP2D6 (0.35) | CYP2D6 | |
| SCHEMBL6905022 | 0.78 | — | — | |
| SCHEMBL21249811 | 0.77 | CYP2D6 (0.34) | CYP2D6 | |
| SCHEMBL21249758 | 0.75 | CYP2D6 (0.37) | CYP2D6 | |
| SCHEMBL18085480 | 0.75 | CHRNA7 (0.40) | CYP2D6SIGMAR1CYP3A4TSHR | |
| SCHEMBL57276 | 0.75 | — | — | |
| SCHEMBL19442063 | 0.75 | CHRNA7 (0.40) | CYP2D6SIGMAR1CYP3A4TSHR | |
| SCHEMBL21973884 | 0.75 | CHRNA7 (0.40) | CYP2D6SIGMAR1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | CYP2D6 3996/4885SIGMAR1 2802/4885CYP3A4 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.